Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate
Autore:
Armstong, VL; Wiggam, MI; Ennis, CN; Sheridan, B; Traub, AI; Atkinson, AB; Bell, PM;
Indirizzi:
Royal Victoria Hosp, Metab Unit, Belfast BT12 6BA, Antrim, North Ireland Royal Victoria Hosp Belfast Antrim North Ireland BT12 6BA , North Ireland Royal Matern Hosp, Belfast, Antrim, North Ireland Royal Matern Hosp Belfast Antrim North Ireland st, Antrim, North Ireland Royal Hosp Trust, Reg Endocrinol Lab, Belfast, Antrim, North Ireland RoyalHosp Trust Belfast Antrim North Ireland ast, Antrim, North Ireland
Titolo Testata:
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
fascicolo: 1, volume: 94, anno: 2001,
pagine: 31 - 37
SICI:
1460-2725(200101)94:1<31:IAAISI>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBESE WOMEN; ORAL-CONTRACEPTIVES; PULSE FREQUENCY; RESISTANCE; SENSITIVITY; ANDROGENS; HYPERINSULINEMIA; METABOLISM; REDUCTION; GLUCOSE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Bell, PM Royal Victoria Hosp, Metab Unit, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland Royal Victoria Hosp Grosvenor Rd Belfast Antrim NorthIreland BT12 6BA
Citazione:
V.L. Armstong et al., "Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate", QJM-MON J A, 94(1), 2001, pp. 31-37

Abstract

Polycystic ovary syndrome (PCOS) is associated with abnormalities of insulin action and insulin secretion. Ethinyl oestradiol/cyproterone acetate is a common agent used to treat the symptoms of PCOS, but its effects on insulin action and insulin pulsatility have not been examined. We investigated the relationship between insulin action and insulin secretion in 11 patientswith PCOS, at diagnosis and after 3 months of treatment with ethinyl oestradiol/cyproterone acetate, and in 13 controls. Insulin action was assessed using the euglycaemic hyperinsulinaemic clamp (2 mU/kg/min for 2 h). Insulin pulsatility was examined over 90 min by 2 min sampling. Short-term insulin pulses were identified using PULSAR. Treatment with ethinyl oestradiol/cyproterone acetate resulted in significant reductions in testosterone (3.3 +/- 0.7 vs. 1.9 +/- 0.2 nmol/l, p < 0.05), free androgen index (10.2 +/- 0.7vs. 1.21 +/- 0.2, p < 0.05) and LH/FSH ratio (2.6 +/- 0.5 vs. 1.0 +/- 0.2,p < 0.05). During hyperinsulinaemic clamps, the glucose infusion rate (CIR) required to maintain euglycaemia was lower in PCOS compared to controls (33.6 +/- 2.7 vs. 45.1 +/- 3.5 <mu>mol/kg/min, p < 0.05) but similar in PCOSbefore and after treatment (33.6 +/- 2.8 vs. 33.6 +/- 2.7 <mu>mol/kg/min, p = 0.9). Numbers of pulses identified in PCOS and controls were similar and unaltered by ethinyl oestradiol/cyproterone acetate. There was no correlation between GIR and frequency of insulin pulses in PCOS before or after treatment (r = 0.2, p = 0.6; post r = -0.5, p = 0.1) unlike controls (r = -0.6, p = 0.04). Despite considerable improvement in androgen profile, treatment with ethinyl oestradiol/cyproterone acetate did not alter insulin actionin PCOS, and this insulin resistance does not appear to be determined by insulin pulse frequency.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 05:02:52